Macrophages in tumors with downregulated MHC-I expression: emerging therapeutic opportunities and translational challenges
Clicks: 1
ID: 324689
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #22 of 30 articles by views in Clinical & Experimental Immunology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Tumor-associated macrophages (TAMs) are the dominant component of the tumor microenvironment (TME) and exhibit remarkable phenotypic plasticity and heterogeneity that extends beyond the classical M1/M2 polarization, as revealed by single-cell transcriptomics across multiple cancer types. Downregulation of major histocompatibility complex class I (MHC-I) on tumor cells is a common immune evasion strategy that profoundly shapes TAM composition and function. Conversely, TAMs reciprocally modulate tumor MHC-I expression. This review provides an overview of the verified and hypothetical mechanisms of bidirectional regulatory interactions between MHC-I on tumor cells and TAMs. Since these interactions likely differ between tumors with reversible and irreversible MHC-I downregulation, their potential significance in tumor immunotherapy should be assessed separately for each MHC-I reduction mechanism.
| Reference Key |
openalex_W7202197416
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Adrianna Piatakova, Michal Šmahel |
| Journal | Clinical & Experimental Immunology |
| Year | 2026 |
| DOI |
10.1093/cei/uxag047
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.